Related Experiment Video
Updated: Jan 22, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
Pulmonary Alveolar Microlithiasis Coexisting With Rheumatic Heart Disease and Severe Pulmonary Hypertension: A Case
Aadithya Shyllesh H1, Tehsim A Memon2, Pranathi Guruswamy1
1Internal Medicine, Ramaiah Medical College Hospital, Ramaiah University of Applied Sciences, Bengaluru, IND.
Abstract:
Pulmonary Alveolar Microlithiasis (PAM) is a rare diffuse lung disease characterized by intra-alveolar calcium phosphate microlith accumulation. Its coexistence with rheumatic valvular heart disease with resultant severe pulmonary hypertension is exceedingly uncommon and poses unique diagnostic and management challenges. This case underscores the importance of maintaining a broad differential diagnosis, emphasizing that new or worsening respiratory symptoms in patients with established cardiac disease should not be automatically attributed to cardiac pathology alone. We report the case of a 63-year-old gentleman with longstanding rheumatic heart disease (RHD) who presented with progressive dyspnoea. Clinical evaluation revealed features suggestive of severe pulmonary hypertension. Investigations confirmed PAM with characteristic "sandstorm" calcifications on chest imaging, supported by bronchoalveolar lavage demonstrating calcospherites and identification of an SLC34A2 gene mutation, alongside rheumatic mitral stenosis. The patient's pulmonary hypertension was attributed to a combination of PAM and RHD. This case illustrates a rare combination of PAM with RHD and severe pulmonary hypertension. It underlines the importance of considering dual pathology in patients with complex cardiopulmonary presentations. Early recognition of PAM, even in the presence of another disease like RHD, is crucial for appropriate management and prognostication. This report adds to the limited literature on such coexistence and highlights the need for multidisciplinary care in these patients.
More Related Videos
07:41A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
Published on: March 1, 2022
07:11Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
Published on: May 23, 2025
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Rheumatic Heart Disease IV: Nursing Management
Rheumatic Heart Disease III: Medical Management
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...